Drug intelligence / Profile preview

VRC-FLUDNA063-00-VP

Development stage: Phase 1
Lead developer: Vaccine Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-FLUDNA063-00-VP is a seasonal influenza DNA vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). It is composed of three closed-circular DNA plasmids that encode for the hemagglutinin (HA) protein from three specific influenza strains: A/California/04/2009 (H1), A/Victoria/361/2011 (H3), and B/Wisconsin/2010. The vaccine aims to induce an immune response against these influenza strains to prevent infection.

Other names: HA DNA VaccineSeasonal influenza trivalent DNA vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on VRC-FLUDNA063-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-FLUDNA063-00-VP.

Explore the full profile